Overview A Long Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea Status: Completed Trial end date: 2020-01-24 Target enrollment: Participant gender: Summary To assess the safety of S5G4T-1 when applied once daily for 24 to 48 weeks in patients with papulopustular rosacea Phase: Phase 3 Details Lead Sponsor: Sol-Gel Technologies, Ltd.